Investigation of porcine circovirus contamination in human vaccines

Biologicals

Volumn 40, Issue 4, 2012, Pages 270-277

  Gilliland, Sarah M ^a   Forrest, Lindsay ^a   Carre, Heather ^a   Jenkins, Adrian ^a   Berry, Neil ^a   Martin, Javier ^a   Minor, Philip ^a   Schepelmann, Silke ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Adventitious agents; Influenza vaccine; MMR; Polio vaccine; Porcine circovirus; Rotavirus vaccine

Indexed keywords

INFLUENZA VACCINE; MEASLES VACCINE; MUMPS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; VIRUS DNA; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; BULK DENSITY; CAP GENE; CIRCOVIRUS; CONTROLLED STUDY; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG QUALITY; DRUG SCREENING; DRUG SYNTHESIS; EMBRYO; GENE DOSAGE; GENE MUTATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERO CELL; VIRUS GENE;

AMINO ACID SEQUENCE; BASE SEQUENCE; CIRCOVIRUS; DNA PRIMERS; DRUG CONTAMINATION; HUMANS; MOLECULAR SEQUENCE DATA; POLIOVIRUS VACCINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

POLIOVIRUS; PORCINE CIRCOVIRUS; PORCINE CIRCOVIRUS 1; ROTAVIRUS; RUBELLA;

EID: 84863785381     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2012.02.002     Document Type: Article

References (31)

1. Shah K., Nathanson N. Human exposure to SV40: review and comment. Am J Epidemiol 1976, 103:1-12.
2. Harasawa R., Tomiyama T. Evidence of pestivirus RNA in human virus vaccines. J Clin Microbiol 1994, 32:1604-1605.
3. Hussain A.I., Johnson J.A., Da Silva Freire M., Heneine W. Identification and characterization of avian retroviruses in chicken embryo-derived yellow fever vaccines: investigation of transmission to vaccine recipients. J Virol 2003, 77:1105-1111.
4. Robertson J.S., Minor P. Reverse transcriptase activity in vaccines derived from chick cells. Biologicals 1996, 24:289-290.
5. Hussain A.I., Shanmugam V., Switzer W.M., Tsang S.X., Fadly A., Thea D., et al. Lack of evidence of endogenous avian leukosis virus and endogenous avian retrovirus transmission to measles, mumps, and rubella vaccine recipients. Emerg Infect Dis 2001, 7:66-72.
6. Victoria J.G., Wang C., Jones M.S., Jaing C., McLoughlin K., Gardner S., et al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol 2010, 84:6033-6040.
7. McClenahan S.D., Krause P.R., Uhlenhaut C. Molecular and infectivity studies of porcine circovirus in vaccines. Vaccine 2011, 29:4745-4753.
8. Baylis S.A., Finsterbusch T., Bannert N., Blumel J., Mankertz A. Analysis of porcine circovirus type 1 detected in Rotarix vaccine. Vaccine 2011, 29:690-697.
9. Global Advisory Committee on Vaccine Safety, 16-17 June 2010. Wkly Epidemiol Rec 2010, 85:285-292.
10. Finsterbusch T., Mankertz A. Porcine circoviruses - small but powerful. Virus Res 2009, 143:177-183.
11. Tischer I., Rasch R., Tochtermann G. Characterization of papovavirus-and picornavirus-like particles in permanent pig kidney cell lines. Zentralbl Bakteriol Orig A 1974, 226:153-167.
12. Li L., Kapoor A., Slikas B., Bamidele O.S., Wang C., Shaukat S., et al. Multiple diverse circoviruses infect farm animals and are commonly found in human and chimpanzee feces. J Virol 2010, 84:1674-1682.
13. Allan G.M., McNeilly F., Cassidy J.P., Reilly G.A., Adair B., Ellis W.A., et al. Pathogenesis of porcine circovirus; experimental infections of colostrum deprived piglets and examination of pig foetal material. Vet Microbiol. 1995, 44:49-64.
14. Kekarainen T., McCullough K., Fort M., Fossum C., Segales J., Allan G.M. Immune responses and vaccine-induced immunity against Porcine circovirus type 2. Vet Immunol Immunopathol 2010, 136:185-193.
15. Morozov I., Sirinarumitr T., Sorden S.D., Halbur P.G., Morgan M.K., Yoon K.J., et al. Detection of a novel strain of porcine circovirus in pigs with postweaning multisystemic wasting syndrome. J Clin Microbiol. 1998, 36:2535-2541.
16. Beach N.M., Cordoba L., Kenney S.P., Meng X.J. Productive infection of human hepatocellular carcinoma cells by porcine circovirus type 1. Vaccine 2011.
17. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
18. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33.
19. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362:289-298.
20. Richardson V., Hernandez-Pichardo J., Quintanar-Solares M., Esparza-Aguilar M., Johnson B., Gomez-Altamirano C.M., et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010, 362:299-305.
21. Atherly D., Dreibelbis R., Parashar U.D., Levin C., Wecker J., Rheingans R.D. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis 2009, 200(Suppl. 1):S28-S38.
22. Kumar D., Beach N.M., Meng X.J., Hegde N.R. Use of PCR-based assays for the detection of the adventitious agent porcine circovirus type 1 (PCV1) in vaccines, and for confirming the identity of cell substrates and viruses used in vaccine production. J Virol Methods 2011.
23. Ranheim T., Mathis P.K., Joelsson D.B., Smith M.E., Campbell K.M., Lucas G., et al. Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq). J Virol Methods 2006, 131:193-201.
24. Berry N., Jenkins A., Martin J., Davis C., Wood D., Schild G., et al. Mitochondrial DNA and retroviral RNA analyses of archival oral polio vaccine (OPV CHAT) materials: evidence of macaque nuclear sequences confirms substrate identity. Vaccine 2005, 23:1639-1648.
25. Kuehn B.M. FDA: Benefits of rotavirus vaccination outweigh potential contamination risk. JAMA 2010, 304:30-31.
26. Committee for Medicinal Products for Human Use. Questions and answers on the review of Rotarix (rotavirus vaccine, live). EMA/CHMP/460465/2010; 2010.
27. Ma H., Shaheduzzaman S., Willliams D.K., Gao Y., Khan A.S. Investigations of porcine circovirus type 1 (PCV1) in vaccine-related and other cell lines. Vaccine 2011.
28. Hattermann K., Roedner C., Schmitt C., Finsterbusch T., Steinfeldt T., Mankertz A. Infection studies on human cell lines with porcine circovirus type 1 and porcine circovirus type 2. Xenotransplantation 2004, 11:284-294.
29. Martin J., Crossland G., Wood D.J., Minor P.D. Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J Gen Virol 2003, 84:1781-1788.
30. Foster K.A., Oster C.G., Mayer M.M., Avery M.L., Audus K.L. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp Cell Res 1998, 243:359-366.
31. Young D.F., Andrejeva L., Livingstone A., Goodbourn S., Lamb R.A., Collins P.L., et al. Virus replication in engineered human cells that do not respond to interferons. J Virol 2003, 77:2174-2181.